Technology Offers Page 99

Yissum - Research Development Company of the Hebrew University posted this:

Opthamology Project ID : 7-2010-2523
A New Ophthalmic  Viscoelastic Device (OVD) for Cataract Surgery

Yissum - Research Development Company of the Hebrew University posted this:

Cluster9 Project ID : 6-2017-4487
Programable Release of 3D-Printed Drugs

Fundació URV posted this:

Leishmaniasis is an endemic parasitic disease that is found in most parts of the tropics, subtropics and southern Europe. Cutaneous Leishmaniasis (CL) is the most common form of Leishmaniasis. It is caused by the protozoan Leishmania parasites, which are transmitted by the bite of infected female phlebotomine sand-flies. Cutaneous Leishmaniasis causes skin lesions, mainly ulcers, on exposed parts of the body, leaving life-long scars and serious disability. The skin lesions usually develop within several weeks or months after exposure. About 95% of Cutaneous Leishmaniasis cases occur in the Americas, the Mediterranean basin, the Middle East and Central Asia. An estimated number of 0.6 million to 1 million cases occur worldwide annually. Over two thirds of new Cutaneous Leishmaniasis cases occur in the next six countries: Afghanistan, Algeria, Brazil, Colombia, Iran and Syria. Cutaneous Leishmaniasis is diagnosed by detecting Leishmania parasites in tissue specimens from skin lesions via light-microscopic examination of stained slides, specialized culture techniques, or molecular methods. This disease is treatable and curable. Early diagnosis and effective case management reduces the prevalence of the disease and prevents disabilities and death. Hence, early detection and prompt treatment of cases would therefore help to reduce transmission and to monitor the spread and burden of the diseases. In this invention, a new system for non-invasive, early, fast and easy to use diagnosis test for Cutaneous Leishmaniasis from exhaled breath analysis has been developed.
New method for the diagnosis of cutaneous leishmaniasis